Jason V. O’Byrne's Insider Trades & SAST Disclosures
Jason V. O’Byrne's most recent trade in Caribou Biosciences Inc was a trade of 153,000 Option to purchase Common Stock done . Disclosure was reported to the exchange on Feb. 20, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jason V. O’Byrne.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Caribou Biosciences Inc | O’Byrne V. Jason | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 153,000 | 153,000 | - | - | Option to purchase Common Stock | |
| Caribou Biosciences Inc | Jason O’Byrne V. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 33,000 | 59,224 | - | 0 | Common Stock | |
| Caribou Biosciences Inc | Jason V. O’Byrne | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 131,000 | 131,000 | - | - | Option to purchase Common Stock | |
| Caribou Biosciences Inc | Jason V. O’Byrne | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.11 per share. | 08 Feb 2022 | 24,336 | 24,336 | - | 4.1 | 100,021 | Common Stock |
| Caribou Biosciences Inc | Jason V. O’Byrne | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2022 | 24,336 | 412,865 | - | - | Option to purchase Common Stock | |
| Caribou Biosciences Inc | Jason V. O’Byrne | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2021 | 147,000 | 147,000 | - | - | Option to purchase Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges